AR and prostate cancer: Furthermore, their upregulation in the context of CHD1 loss was reversible, as revealed by doxycycline-regulated CHD1 shRNA knockdown (Figure 6D) and was evident in three other AR-positive human prostate cancer cell lines (Figures S6A–S6C).